Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra is back

This article was originally published in The Tan Sheet

Executive Summary

American Generics Laboratories has launched four new ephedra-containing weight-loss supplements "as a result of high consumer demand following the recent overturning of the 2004 FDA ban on ephedra-based products," according to an announcement Nov. 16. The Salt Lake City, Utah-based firm was founded in August and is marketing Superdrine RX-10, Ripped Power, Metabothin and Super Ephedra Extreme online for $39.99 - $59.99. "The products are manufactured in FDA-approved facilities and are of daily dosages permitted by law," the firm maintains. FDA banned dietary supplements containing ephedrine alkaloids in 2004. However, a Utah District Court overturned the ban in April for Nutraceutical Corporation's 10 mg product. FDA is appealing the court's decision (1"The Tan Sheet" Nov. 14, 2005, p. 4)...

You may also be interested in...

“No Evidence” Exists That Ephedra Ban Shifted Burden Of Proof, Agency Says

No evidence has been presented that FDA's use of a risk/benefit analysis in its decision to ban ephedra shifted the burden of proof onto industry, the agency says

EU ‘Structured Dialog’ Offers Opportunity To Secure Supply

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.

Adcock Struggles As South African Healthcare Awaits Relief

Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts